The activation of mGluR4 rescues parallel fiber synaptic transmission and LTP, motor learning and social behavior in a mouse model of Fragile X Syndrome.
Ricardo Martín, Alberto Samuel Suárez-Pinilla, Nuria García-Font and 7 others
PMID 37029391WHAT IT FOUND
In mice with Fragile X syndrome, a drug activating mGluR4 receptors restored cerebellar synaptic plasticity.
This improved motor learning in skilled reaching and eyeblink conditioning, and normalized social interaction behaviors compared to untreated mice.
Key findings
01The drug VU 0155041 restored parallel fiber to Purkinje cell Long Term Potentiation (LTP) in Fragile X mice.
02Treatment improved motor learning deficits in skilled reaching and classical eyeblink conditioning tasks.
03The drug reversed deficits in sociability and social novelty behaviors.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is an animal study; findings do not directly translate to human clinical practice. Systemic administration of the drug may affect many neurons and circuits across several brain regions, not just the cerebellum. The drug was administered as a single dose in most tests; the effects of chronic administration are unknown.
Declared interests
Funded by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, Comunidad de Madrid, Ministerio de Ciencia e Innovación, Universidad Complutense de Madrid, and Junta de Andalucía. No commercial conflicts declared.
The easy way to misread this
Do not assume this drug is ready for human use. This is a preclinical mouse study. The improvement in motor and social behaviors was seen in a genetic model of Fragile X syndrome, not in human patients, and the drug's safety and efficacy in humans have not been tested here.